# China approves sac-TMT for EGFR-mutant lung cancer, the first TROP2 conjugate approved in lung cancer

Canonical page: https://technooptimist.io/stories/china-approves-sac-tmt-for-egfr-mutant-lung-cancer-the-first-trop2-36f82d84
Date: 10 Mar 2025
About: [Merck & Co.](https://technooptimist.io/companies/merck.md) · [Sacituzumab tirumotecan (sac-TMT)](https://technooptimist.io/biotech/sac-tmt.md)
Original source: https://filingreader.com/news-wire/shenzhen/2025-03-17/keluns-sac-tmt-lung-cancer-treatment-approved-in-china

Kelun-Biotech won Chinese approval for sac-TMT as second-line treatment of EGFR-mutant lung cancer, its second indication in China. The approval rested on the OptiTROP-Lung03 trial, which beat docetaxel chemotherapy on response, progression-free survival and overall survival. Merck holds the rights everywhere outside Greater China.

## Key facts

- Brand name in China: Jiatailai; disclosed by Sichuan Kelun Pharmaceutical on 10 Mar 2025.
- Described as the first TROP2 conjugate approved for lung cancer anywhere.
- Merck licensed ex-China rights in May 2022.

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.